Indications for VEMLIDY:
Chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.
Test for HIV-1 infection prior to initiation. Take with food. ≥18yrs: 1 tab once daily. Concomitant carbamazepine: 2 tabs once daily. Hemodialysis: give after session.
<18yrs: not established.
Post-treatment severe acute exacerbation of hepatitis B.
Discontinuation of anti-HBV therapy may be associated with severe acute exacerbations of hepatitis B. Closely monitor patients for several months after stopping treatment; if appropriate, anti-HBV therapy may be warranted. HBV and HIV-1 coinfection: not recommended as monotherapy for treatment of HIV-1 infection (risk of developing HIV-1 resistance). Suspend therapy if lactic acidosis or pronounced hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Discontinue if significant renal dysfunction or Fanconi syndrome develops. Assess SCr, estimated CrCl, urine glucose, urine protein in all patients, and serum phosphorus (in chronic kidney disease) before initiating and during therapy. Decompensated hepatic impairment (Child-Pugh B or C) or ESRD (CrCl <15mL/min) not on hemodialysis: not recommended. Pregnancy. Nursing mothers.
Nucleoside analogue (reverse transcriptase inhibitor).
Concomitant oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, St. John's wort: not recommended. Antagonized by carbamazepine (see Adults). Concomitant drugs that strongly affect P-gp and BCRP activity may lead to changes in TAF absorption. Caution with concomitant nephrotoxic agents. May be potentiated by drugs that decrease renal function or compete for active tubular secretion (eg, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides, high-dose or multiple NSAIDs).
Headache, abdominal pain, cough, fatigue, nausea, back pain.
Register pregnant patients in the Antiretroviral Pregnancy Registry (APR) by calling (800) 258-4263.